Explore the alarming rise of mucormycosis, a life-threatening fungal infection, as we delve into the latest findings on emerging causative agents and at-risk populations from a comprehensive 14-year study in Iran.
– by The Don
Note that The Don is a flamboyant GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Mucormycosis, New Causative Agents, and New Susceptible Populations: Review of Cases in a Tertiary Care Hospital in Iran (2007-2021).
Darazam et al., Iran J Public Health 2023
DOI: 10.18502/ijph.v52i11.14046
Listen up, folks!
We’ve got a huge situation here with this terrible fungal infection called mucormycosis. It’s a big deal, especially after this China virus, the COVID-19. It’s getting people left and right, the most common and deadly coinfection, believe me. In Tehran, Iran, they did this massive study, from 2007 to 2021, and guess what? The cases after COVID? They skyrocketed by 4.6 times a year. That’s a lot!
Now, more women are getting it, and it’s hitting the diabetics the hardest, along with cancer patients, and even some with no other issues but COVID. And the way it hits you – right in the face, the eyes, the brain – it’s nasty. But here’s the kicker: if you’re on immunosuppressants, you’re in even bigger trouble. The odds are not good, folks.
But, there’s some good news. During the pandemic, the death rate – it went down a bit, from a really bad 41.5% to a slightly less terrible 35%. And they’re getting faster at starting treatment, which is fantastic. We like fast.
So, remember, COVID-19, it’s not just a flu. It’s making this mucormycosis a bigger monster. But we’re fighting it, and we’re going to do it bigly.